Senesco Technologies, Inc. (SNT) Announces IND Filing with FDA for SNS01-T  
1/24/2011 8:01:43 AM

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced that the Company has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for Senesco’s lead drug candidate SNS01-T for treatment of multiple myeloma.